HLS Therapeutics (TSE:HLS) Issues Quarterly Earnings Results

HLS Therapeutics (TSE:HLS) posted its earnings results on Wednesday. The company reported C($0.04) EPS for the quarter, FiscalAI reports. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. The business had revenue of C$21.24 million during the quarter. During the same quarter in the prior year, the company posted ($0.09) EPS.

Here are the key takeaways from HLS Therapeutics’ conference call:

• Cardiovascular portfolio growth accelerated: Q2 net sales rose 25% year over year, led by 18% Vascepa growth and NILEMDO’s first full quarter of sales exceeding $300,000.
• NILEMDO access and uptake are progressing ahead of plan. Nearly 1,200 patients had started treatment by the end of Q2, private-payer coverage now reaches approximately 80% of privately insured Canadians, and public reimbursement negotiations are expected to begin later this year.
• Additional growth catalysts are approaching: NEXLIZET remains on track for a Health Canada decision by year-end and a potential launch in the first half of 2027, while management expects NILEMDO momentum to strengthen in the second half of 2026.
• CLOZARIL trends were mixed but improving in Canada. The Canadian branded patient base grew for five consecutive months and Q2 sales declined only 1%, while U.S. sales fell to $3.0 million; management expects relatively flat U.S. year-over-year comparisons in the second half.
• Management reaffirmed 2026 guidance of CAD 56–60 million in revenue and CAD 18.5–21 million in Adjusted EBITDA, citing expected second-half margin expansion, lower interest costs, debt reduction, and an active share buyback program.

HLS Therapeutics Price Performance

HLS stock traded up C$0.13 during trading on Wednesday, hitting C$3.96. The company had a trading volume of 49,010 shares, compared to its average volume of 19,466. The firm has a market capitalization of C$123.85 million, a price-to-earnings ratio of -12.38 and a beta of -0.18. The business has a 50 day moving average of C$4.25 and a 200 day moving average of C$4.42. HLS Therapeutics has a fifty-two week low of C$3.81 and a fifty-two week high of C$5.77. The company has a current ratio of 1.00, a quick ratio of 1.01 and a debt-to-equity ratio of 75.00.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.